Abide Therapeutics

Our mission is to develop innovative medicines for the benefit of human health that target serine hydrolases, one of the largest enzyme classes in Nature with validated, but mostly untapped therapeutic potential. Hundreds of serine hydrolases exist in humans and include lipases, amidases, esterases, thioesterases, proteases and peptidases, which all share a base-activated serine nucleophile that cleaves an amide or ester bond. Serine hydrolases play a key role in regulating CNS signaling, digestion, metabolism, inflammation, blood clotting, life cycle of viruses and pathogens. The Abide technology selectively and near-universally targets this enzyme class in their native configuration for functional profiling and inhibitor discovery and optimization.
Company Growth (employees)
Type
Private
HQ
San Diego, US
Founded
2011
Size (employees)
39 (est)-2%
Abide Therapeutics was founded in 2011 and is headquartered in San Diego, US

Key People/Management at Abide Therapeutics

Alan Ezekowitz

Alan Ezekowitz

President, Co-Founder, CEO
Stan Blackburn

Stan Blackburn

CFO

Abide Therapeutics Office Locations

Abide Therapeutics has offices in San Diego and Princeton
San Diego, US (HQ)
250 10835 Rd to the Cure
Princeton, US
230 Nassau St

Abide Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2011

Total Funding

$2.3 m

Latest funding size

$2.3 m

Time since last funding

about 6 years
Abide Therapeutics's latest funding round in November 2011 was reported to be $2.3 m. In total, Abide Therapeutics has raised $2.3 m

Abide Therapeutics's Web-traffic and Trends

Abide Therapeutics Company Life and Culture

You may also be interested in